EU/3/00/010

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2016 at the end of the period of market exclusivity.

On 29 December 2000, orphan designation (EU/3/00/010) was granted by the European Commission to Shire Pharmaceutical Development Ltd, United Kingdom, for anagrelide hydrochloride for the treatment of essential thrombocythaemia.

The sponsorship was transferred to Shire Pharmaceuticals Contracts Ltd, United Kingdom, in December 2001.

Anagrelide hydrochloride has been authorised in the EU as Xagrid since 16 November 2004.

More information on Xagrid can be found in the European public assessment report (EPAR) on the Agency's website.

Key facts

Active substance
Anagrelide hydrochloride
Medicine name
Xagrid
Disease / condition
Treatment of essential thrombocythaemia
Date of decision
29/12/2000
Outcome
Expired
Orphan decision number
EU/3/00/010

Sponsor's contact details

Shire Pharmaceuticals Contracts Ltd
Hampshire International Business Park
Chineham, Basingstoke
Hants RG24 8EP
United Kingdom
Telephone: +44 12 56 89 40 00
Telefax: +44 12 56 89 47 08
E-mail: medinfoglobal@shire.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating